James Chamberlain, MD
Internal Medicine · Salt Lake City, UTNPI 1093805681
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $65,730 of the $106,389 with a category attached, or 61.8%. 43 manufacturers reported payments, led by Dexcom, Inc. at 33.0% of the total. Among internal medicine clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 646 payments — averaging $164.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$35K
- Abbott$22K
- Novo Nordisk$14K
- Johnson & Johnson$12K
- Tandem Diabetes Care, Inc.$12K
- Sanofi-aventis U.S. LLC$2K
- plus $9K from 37 others
What the payments were for
- Consulting fees$12,62212%
- Speaking & faculty fees$65,73062%
- Travel & lodging$8,6178%
- Food & beverage$19,30018%
- Education$1200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$18,976
- INVOKANA$12,300
- FreeStyle Libre Pro$12,260
- t:slim X2 Insulin Pump with Control-IQ$11,194
- Ozempic$7,960
- DEXCOM G7 GSS (161)$6,656
- DEXCOM G6 CGM SYSTEM$6,136
- Victoza$4,320
- FreeStyle Libre$2,789
- FreeStyle Libre 2$1,935
- FREESTYLE LIBRE 3$1,655
- DEXCOM CGM$1,595
- TZIELD$905
- iLet Bionic Pancreas$743
- HUMULIN$731
- InPen$616
- INPEN SMART INSULIN DELIVERY SYSTEM$562
- Afinion 2$300
- ALERE AFINION HBA1C CONTROL$300
- Omnipod$276
How this compares
$106,389 in reported general payments places this provider in the 95th percentile of 496 internal medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 130 | $178,205 |
| JardianceEmpagliflozin | 121 | $144,066 |
| JanuviaSitagliptin Phosphate | 89 | $97,333 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 60 | $88,558 |
| Tresiba Flextouch U-100Insulin Degludec | 75 | $84,123 |
| MounjaroTirzepatide | 75 | $79,028 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $56,979 |
| TrulicityDulaglutide | 34 | $51,497 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 69 | $39,554 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 25 | $39,410 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $33,853 |
| Humalog Kwikpen U-100Insulin Lispro | 56 | $27,148 |
| FarxigaDapagliflozin Propanediol | 16 | $26,174 |
| HumalogInsulin Lispro | 65 | $22,882 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $22,582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $13,563 | $231,823192 claims |
| Boehringer IngelheimJardiance, Tradjenta | $758 | $165,402146 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $1,570 | $158,378215 claims |
| MerckJanuvia, Janumet | $598 | $119,915104 claims |
| AstraZenecaFarxiga | $155 | $26,17416 claims |
| Sanofi-aventis U.S. LLCLantus | $2,176 | $16,04139 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 496 internal medicine providers in Utah.
Other internal medicine in Salt Lake City
- Willard DereSalt Lake City$4.7M
- Alexander PastuszakSalt Lake City$87K
- Zameer AbedinSalt Lake City$83K
- Gerald GleichSalt Lake City$22K
- Brian HornerSalt Lake City$21K
- Rachel HessSalt Lake City$18K
- Linda VennerSalt Lake City$8K
- David KuoSalt Lake City$8K
- Evan DaughertySalt Lake City$6K
- Margaret LuntSalt Lake City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.